Assignee
ELPIS BIOPHARMACEUTICALS
US·0 granted patents·10 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
10 records- 0166US2025326813A1Engineered interleukin-2 receptor beta reduced-binding agonistELPIS BIOPHARMACEUTICALS·Filed 2023·Application pending·0 cites
- 0263US2026097076A1Chimeric antigen receptors specific to b-cell mature antigen (bcma) and/or transmembrane activator and caml interactor (taci)ELPIS BIOPHARMACEUTICALS·Filed 2023·Application pending·0 cites
- 0357US2024368275A1Anti-nectin4 antibodies and multi-specific protein complexes comprising suchELPIS BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 0457US2025340646A1Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15, interleukin-15 receptor alpha, or interleukin-2ELPIS BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 0556US2024336683A1Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereofELPIS BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 0654US2023220053A1ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOFELPIS BIOPHARMACEUTICALS·Filed 2021·Application pending·0 cites
- 0751US2024082402A1Bispecific chimeric antigen receptors binding to cd19 and cd22ELPIS BIOPHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 0849US2022298257A1Anti-cd22 antibodies and uses thereofELPIS BIOPHARMACEUTICALS·Filed 2020·Application pending·0 cites
- 0949US2022289843A1Anti-cd19 antibodies and uses thereofELPIS BIOPHARMACEUTICALS·Filed 2020·Application pending·0 cites
- 1046US2023002466A1Engineered interleukin-2 receptor beta agonistsELPIS BIOPHARMACEUTICALS·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ELPIS BIOPHARMACEUTICALS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →